

CV- Guido Kroemer

Personal data: Guido Kroemer (born in Germany in 1961) is an Austrian and Spanish citizen, living in France as a permanent resident since 1993. He is fluent in German, English, French, Italian and Spanish.

Present positions: Guido Kroemer is currently (since 2010) Professor at the Faculty of Medicine of the University of Paris Descartes, Director of the research team "Apoptosis, Cancer and Immunity" of the French Medical Research Council (INSERM), Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Comprehensive Cancer Center, and Hospital Practitioner at the Hôpital Européen George Pompidou, Paris, France. He is also Foreign Adjunct Professor at the Karolinska Institute, Stockholm, Sweden, as well as Honorary Professor at the Suzhou Center of Systems Medicine, Chinese Academy of Sciences. Kroemer is the Founding Director of the European Research Institute for Integrated Cellular Pathology (ERI-ICP), the Director of the LabEx Immuno-Oncology, and the Founding President of the European Academy of Tumor Immunology (EATI).

Past positions: Prior to joining the French Medical Research Council (INSERM, 1994-2010), Dr. Kroemer was Senior Scientist of the European Community at the Spanish National Research Council (CSIC), at the National Center of Molecular Biology (1990-1992) and at the National Center of Biotechnology (1993). Dr. Kroemer did his post-doctoral training at the Collège de France, Nogent-sur-Marne (1988-1989), and at the University of Innsbruck, Austria, after receiving his PhD/MD degree at the same University in 1985. He also holds a PhD degree in Molecular Biology (Autonomous University of Madrid, 1992). Other short-term appointments include a lectureship at Wayne State University in Detroit (1984), a sabbatical at University of California San Francisco (1992), a Burnham fellowship at the Burnham Sanford Institute in San Diego (1999/2000), and a visiting professorship at University of Rome Tor Vergata (2013/2014). He holds honorary doctoral degrees from the University of Buenos Aires (2011) and the University of Rome Tor Vergata (2018). He was the Director of the Paris Alliance of Cancer Research Institutes (PACRI) from 2013 to 2017.

Scientific contributions: Dr. Guido Kroemer has made important contributions to medical research through his groundbreaking work in the fields of cell biology and cancer research. He is best known for the discovery that the permeabilization of mitochondrial membranes constitutes a decisive step in programmed cell death. Kroemer has explored the fine mechanisms of mitochondrial cell death control, the molecular pathways that explain the inhibition of cell death in cancer cells, upstream of or at the level of mitochondria, and the mechanisms that make cancer cell death immunogenic. In recent years, he has worked on the link between cellular stress and autophagy, as well as the stimulation of autophagy for improving health span and lifespan in model organisms. His work has had far reaching implications for the comprehension, detection and therapeutic manipulation of cellular demise. He has published some 1080 papers (350 among which in the last 5 years) including in Science (14x), Cell (11x), Nature (5x), Nature Medicine (14x), Journal of Experimental Medicine (25x), EMBO Journal (19x), Journal of Clinical Investigation (15x), Molecular Cell (13x), Cell Research (11x), Nature Cell Biology (11x), Immunity (9x), Cell Reports (8x), Nature Immunology (6x), Cell Metabolism (5x), Journal of Cell Biology (5x), Cancer Cell (4x), Science Translational Medicine (4x), Nature Communications (3x), Nature Structural Biology (2x), Proceedings of the National Academy of Sciences of the USA (2x), and New England Journal of Medicine, among many others. At the end of 2017, these papers have been

cited >185,000 times (h-index=203) according to Google Scholar and >135,000 times according to the Web of Science (Thomson Reuters) (h-index=178; mean citations >103 for 1270 citable items).

Editorial activities: Guido Kroemer is the founding Editor-in-Chief of five journals: Cell Death & Disease (Nature Publishing Group, Springer), Cell Stress (Shared Science), OncoImmunology (Taylor & Francis), Microbial Cell (Shared Science), and Molecular & Cellular Oncology (Taylor & Francis). He is the Deputy Editor of Cell Death & Differentiation. In addition, he serves on the Editorial Boards of Cell Death & Discovery, Cell Discovery, Cell Research, EMBO Journal, EMBO Molecular Medicine, Oncotarget, Molecular & Cellular Biology, Signal Transduction and Targeted Therapy, and Science Signaling.

Memberships: Guido Kroemer is member of the European Molecular Biology Organization (EMBO), German Academy of Sciences (Leopoldina), Austrian Academy of Sciences, Academia Europaea, European Academy of Sciences (EAS), European Academy of Sciences and Arts (EASA), European Academy of Cancer Sciences (EACS), and Institut Universitaire de France (IUF). He is president of the Nomenclature Committee on Cell Death (NCCD), president of the Scientific Advisory Board (SAB) of the FINBA (Fundación para la Investigación Biosanitaria en Asturias, Spain), and member of the SABs of Regina Elena National Cancer Research Institute, Rome, Italy; European Alliance for Immuno-Oncology (EAIO); European Research Institute on Cystic Fibrosis (Milan, Italy); Center for Geroscience, Brain Health and Metabolism (Chile); and Cancer Immunotherapy (CIMT, Mainz, Germany).

Awards: Guido Kroemer's contributions have been recognized with several awards, including the Monika Kutzner Prize of the Berlin-Brandenburg Academy of Sciences (1998), the Gallet & Breton Prize of the French Academy of Medicine (1999), the Descartes Prize of the European Union (2006), the Carus Medal of the German Academy of Sciences (2007), the Grand Prix Mergier-Bourdeix of the French Academy of Sciences (2007), the Lucien Dautrebande Prize of the Belgian Royal Academy of Medicine (2009), the Duquesne Prize of the French National League against Cancer (2010), the 'Coup d'Elan' Prize of the Bettencourt-Schueller Foundation (2011), the Léopold Griffuel Prize of the French Association for Cancer Research (2012), a European Research Council (ERC) Advanced Investigator Award (2013), the Mitjavile Prize of the French Academy of Medicine (2014), the Galien Prize for Pharmacological Research (2015), the Grand Prix Claude Bernard of the City of Paris (2016), the Brupbacher Prize for Cancer Research (2017), the ADPS Prize for Longevity Research (2017), and the Baillet-Latour Health Prize (2018), among others.

Grant support: Kroemer is supported by the Ligue contre le Cancer Comité de Charente-Maritime (équipe labélisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Chancellerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; the European Commission (ArtForce); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the Searave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).